|
Synonyms: ESK-001 | ESK001
Compound class:
Synthetic organic
Comment: The chemical structure for envudeucitinib was obtained from proposed INN list 130 (Feb. 2024), in which the compound is described as a Janus kinase inhibitor with anti-inflammatory potential. It was later disclosed as an orally bioavailable allosteric TYK2 inhibitor, with company code ESK-001 [1,3]. Envudeucitinib targets the allosteric pseudokinase structural domain (JH2) of TYK2.
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Envudeucitinib (ESK-001) was progressed as a clinical candidate for potential to treat inflammatory conditions including plaque psoriasis, SLE and uveitis. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06586112 | A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis | Phase 3 Interventional | Alumis Inc | ||
| NCT06588738 | A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 | Phase 3 Interventional | Alumis Inc | ||
| NCT06846541 | Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis | Phase 3 Interventional | Alumis Inc | ||
| NCT05600036 | A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis | Phase 2 Interventional | Alumis Inc | 2 | |